SCHEMBL2315078

SCHEMBL2315078

CC(C)(NC(=O)Nc1ccc(Cl)c(C(F)(F)F)c1)C(=O)Nc1nc(-c2ccccc2)c(Cc2ccccc2)s1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.49
BLM P54132 1/20 0.45
TRPV1 Q8NER1 4/20 0.44
KDR P35968 3/20 0.43
RORC P51449 1/20 0.43
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
XBP1 P17861 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CASR P41180 1/20 0.42
PLTP P55058 2/20 0.42
GRM4 Q14833 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
AR P10275 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2317569 0.91 AR (0.52) DHODHBLMKDRRORCMAPT
SCHEMBL2316339 0.86 RORC (0.47) DHODHRORCMAPTPLTP
SCHEMBL2317084 0.86 MAPT (0.45) RORCGAAMAPTMAPK1KMT2A
SCHEMBL2318318 0.83 FPR2 (0.46) RORCGAAMAPTKMT2APLTP
SCHEMBL2312708 0.83 TP53 (0.50) RORCGAAMAPTSMN1; SMN2PLTP
SCHEMBL2360023 0.81 TRPV1 (0.49) DHODHTRPV1RORCMAPTMAPK1
SCHEMBL2358812 0.80 TRPV1 (0.46) DHODHTRPV1RORCMAPTMAPK1
SCHEMBL2490168 0.78 PLTP (0.51) RORCKMT2ASMN1; SMN2PLTP
SCHEMBL2316628 0.78 RORC (0.48) RORCGAAMAPTKMT2ASMN1; SMN2
SCHEMBL2484995 0.77 PLTP (0.51) DHODHRORCKMT2ASMN1; SMN2PLTP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
EP-2349484-A2 HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS Novartis AG (CH) 2011-08-03 EP disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed
WO-2010007046-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 DHODH 182/4885BLM 3519/4885TRPV1 2529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.